19 results about "Weight growth" patented technology

The present disclosure provides an aquarium feed with slow-release function, and preparation method and uses thereof. Raw materials of the aquarium feed comprise granulated feeds with different particle sizes and slow-release binding agent; the granulated feeds with different particle sizes are bonded by the slow-release binding agent; the slow-release binding agent contains attractant and slow-release adhesive; and the slow-release adhesive is gel-like in water. The aquarium feed in the present disclosure can be slowly released into tiny particles with uneven size in water, allowing aquarium creatures with different body sizes or living in different water layers (comprising surface, middle and bottom layers) to find suitable food for themselves, thus improving the feed utilization rate and aquarium creatures' weight growth rate, and reducing difference of the body length.

The invention relates to the technical field of aquaculture, in particular to an accurate regulation and control method for micropterus salmoides culture water quality. According to the micropterus salmoides culture water quality regulation and control method, a culture water body meets one or more of the following conditions: (1) adding photosynthetic bacteria into the culture water body every day, and controlling the final concentration of the photosynthetic bacteria in the water body to be 10 < 6 >-10 < 7 > CFU / mL; (2) adjusting the content of dissolved oxygen in the culture water body to 5.5-7.5 mg / L; (3) adjusting the temperature of the culture water to 26 + / -1 DEG C in the daytime and 23 + / -1 DEG C at night. The total nitrogen, total organic carbon and chemical oxygen demand can be obviously reduced through day and night temperature regulation and addition of photosynthetic bacteria, the water change demand is reduced, and the eutrophication risk is reduced; meanwhile, the specific growth rate (SGR) and the weight growth rate (WGH) are improved, the immune and antioxidant indexes are optimized, and the aeration energy consumption is reduced by controlling dissolved oxygen to be 7.0 mg / L.

The present application belongs to the field of veterinary medicine, and specifically discloses a traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis, a preparation method and application thereof. The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Ephedra 12 parts, apricot kernel 12 parts, licorice 9 parts, coix seed 30 parts, forsythia 12 parts, honeysuckle 20 parts, white eupatorium 12 parts, smilax 20 parts, and purple violet 6 parts. The composition can be used for preventing and treating artificially infected IBV chicks, and can significantly improve the survival rate of chicks, alleviate the decrease in body weight growth caused by IBV, relieve clinical symptoms, reduce the viral load in trachea and kidney tissues, reduce organ pathological damage, and promote the recovery of the body. The traditional Chinese medicine composition for preventing and treating chicken infectious bronchitis is easy to obtain, rich in resources, low in cost, safe, non-toxic and non-residual, and the preparation method is simple and suitable for large-scale production.

The application discloses a method for relieving the adverse effects of chronic restraint stress on animals by adding sodium isovalerate into feed, which comprises taking C57BL / 6J mice as research objects, studying the effects of sodium isovalerate on growth performance, depression behavior and intestinal barrier and inflammation indexes of the mice with chronic restraint stress, recording daily weight gain and feed intake, and performing tail suspension test and Elisa test and other test methods, and proving that sodium isovalerate can relieve the decrease of mouse weight growth rate, the increase of feed to weight ratio and the decrease of organ index caused by CRS; through fluorescence quantitative PCR and Western Blot and other methods, it is proved that sodium isovalerate can relieve the intestinal injury of the CRS mice, reduce the expression of colon pro-inflammatory factors and improve the expression of tight junction proteins, and can also reduce the phosphorylation level of NF-kappa B in the colon of the CRS mice. The application explores the relieving effect of sodium isovalerate on chronic restraint stress of animals, so as to provide some theoretical basis for relieving stress in actual production and the application of sodium isovalerate in feed additives.

The invention discloses an sNPF gene and application of an inhibitor of the sNPF gene in prevention and control of beet armyworms, and belongs to the technical field of biology. The sNPF gene of the beet armyworm is silenced through an RNA interference technology, and the sNPF is found to play an important regulation role in ingestion, growth and development and energy metabolism of larvae; the sNPF gene silencing obviously reduces the feeding amount and the body weight growth rate of the larvae, and increases the death rate of the larvae under hunger stress; in addition, silence of the sNPF gene also significantly affects the content of glycometabolism substances in the larva body. The sNPF is found to be a key factor for regulating and controlling the physiological process of beet armyworm larvae, has the potential of serving as a new target for pest control, and provides a theoretical basis for prevention and control of beet armyworms.

The invention discloses application of hippuric acid in activation of brown adipose tissue heat production and prevention and treatment of obesity, and the application is realized by activating brown adipose tissue heat production, specifically, expression of uncoupling protein 1 in brown adipose tissue is up-regulated, heat production capacity under cold stimulation conditions is enhanced, weight gain and abnormal glucose and lipid metabolism are improved, and the purpose of preventing and treating obesity is achieved. The hippuric acid is preferably derived from walnut oil or metabolites thereof, and has a good application prospect.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

Provided herein is a method of reducing weight loss, increasing weight, increasing rate of weight gain, and / or treating failure to thrive in a patient, including administering to the patient vibrotactile stimulation for a duration and frequency sufficient to reduce weight loss, increase weight, increase rate of weight gain, and / or treat failure to thrive in the patient.

The application provides a use of perillaldehyde in preparation of a medicine for treating postpartum lack of lactation, and animal experiments show that perillaldehyde can effectively increase the lactation of postpartum lack of lactation female mice, significantly increase the litter weight growth rate of postpartum lack of lactation female mice, and improve the pathological state of mammary gland tissue of postpartum lack of lactation female mice. In addition, perillaldehyde has good safety and almost no side effects on the body. Therefore, the perillaldehyde described in the application can be used as an active ingredient and applied to preparation of a medicine for treating postpartum lack of lactation, thereby developing a new use of perillaldehyde and providing a new selection for preparation of a medicine for promoting lactation secretion and treating postpartum lack of lactation.

The invention relates to the technical field of poultry breeding, and discloses a poultry house environment self-adaptive regulation and control method and system. The method comprises the following steps: acquiring poultry physiological data through a sensor array to obtain a weight growth rate curve and a metabolic intensity fluctuation curve, and determining a physiological demand vector in combination with a preset feather development model; the poultry feather development degree is evaluated based on the physiological demand vector, a quantitative score is obtained, the relevance between the quantitative score and the physiological demand vector is analyzed, and a wind speed adjustment parameter is calculated based on the relevance; based on the wind speed adjusting parameters, generating an airflow distribution mode sequence, judging whether fluctuation abnormity exists or not, obtaining a wind speed control signal, transmitting the wind speed control signal to ventilation equipment, and adjusting wind speed intensity and ventilation frequency; collecting air quality feedback data in the poultry house in real time, inputting the data into the feather development model, determining a physiological demand vector adjustment value of the next period, and generating a breeding benefit evaluation report according to the adjustment value and the dynamic fluctuation data. The poultry breeding efficiency is improved.

The invention discloses application of MUSTN1 in promoting weight gain and intramuscular fat deposition of chickens, and belongs to the technical field of biological agriculture. According to the invention, the MUSTN1 gene and the encoding protein thereof are creatively applied, so that the synergistic improvement of chicken weight gain and intramuscular fat deposition is realized. The invention reveals for the first time that the over-expressed MUSTN1 gene can significantly increase the intramuscular fat (IMF) content while promoting the chicken weight increase, and effectively solves the long-standing technical bottleneck that the growth speed is negatively related to the meat flavor in commercial broiler chicken breeding. Test data show that the MUSTN1 overexpression enables the breast muscle IMF content of the Gushi chicken to be increased from 1.47% to 2.60%, the leg muscle IMF content of the Gushi chicken to be increased from 3.49% to 4.13%, and the weight of the Gushi chicken to be increased from 1507 g to 1707 g.

The invention discloses a feed additive for increasing weight of fat pigs before slaughtering and a preparation method of the feed additive, and belongs to the technical field of feed additives. Comprising the following steps: taking hermetia illucens, locusta chinensis and silkworm chrysalis, removing impurities, sterilizing, cleaning, drying, putting into an oil press, extracting grease, centrifugally separating, removing impurities, and collecting a clean oil phase to obtain a material A; mixing a mulberry leaf extract, an aralia mandshurica root extract, an opuntia ficus-indica extract, a hippophae rhamnoides seed extract, a honeysuckle flower extract and deionized water to obtain a material B; mixing the material A with polyethylene glycol glycerol ricinoleate, and homogenizing to obtain a material C; and mixing the material B, the material C and Arabic gum, homogenizing, performing vacuum freeze drying, grinding and sieving to obtain the feed additive, and the weight gain growth of the fat pigs can be promoted through the synergistic effect of all the components.

The application belongs to the technical field of feed additives, and particularly relates to application of cytidine diphosphate ethanolamine in preparation of products for promoting animal growth or improving animal muscle performance. The application obtains the key metabolite cytidine diphosphate ethanolamine related to animal muscle performance through multi-omics joint analysis screening, the key metabolite cytidine diphosphate ethanolamine is derived from an animal body, is a key intermediate in phosphatidylethanolamine (PE) biosynthesis, and participates in CDP-Etn pathway regulation. The cytidine diphosphate ethanolamine can be applied in feed, feed additives or health products in a specific adding mode and dose, is suitable for various breeding animals such as rodents, poultry and mammals, and can significantly improve average daily feed intake, body weight growth rate, increase chest muscle weight, improve chest muscle rate and enhance grip strength.

The invention discloses a weight-reducing medicine with siraitia grosvenorii pomace water extract as an active ingredient and application of the weight-reducing medicine, and belongs to the technical field of biological medicine. The weight-reducing medicine with the siraitia grosvenorii pomace water extract as the active ingredient has the effects of reducing fat deposition, delaying weight gain and the like, and can effectively reduce animal abdominal fat deposition, relieve liver fatty lesion, slow down animal weight gain and reduce the fat content in animal bodies after being added into animal feed or daily ration; good application prospects are realized.

Provided herein is a method of reducing weight loss, increasing weight, increasing rate of weight gain, and / or treating failure to thrive in a patient, including administering to the patient vibrotactile stimulation for a duration and frequency sufficient to reduce weight loss, increase weight, increase rate of weight gain, and / or treat failure to thrive in the patient.

The application discloses application of a copper-containing compound in preparation of a medicine for preventing and / or treating obesity and related metabolic diseases. The application breaks through the traditional cognition on safety of high-dose copper, and proves that oral administration of the copper-containing compound (such as copper chloride) in a specific dose range (calculated according to copper element, such as 0.07-2.84 mg / kg body weight per day) can effectively inhibit weight growth of animals induced by a high-fat diet, and simultaneously has an effect on liver steatosis and body composition, without risk of liver toxicity. Compared with existing weight loss methods, the application scheme has the advantages of low raw material price, convenient oral use, wide safety window, remarkable comprehensive effect and the like, and provides a clear direction and a solid experimental basis for development of a new, economical and safe medicine or health care food for preventing and treating obesity.

The invention discloses an application of Muraculum gardroncarteri in preparation of a product for preventing and / or treating obesity and related diseases of the obesity, and particularly discloses an application of the Muraculum gardroncarteri in preparation of a product for preventing and / or treating obesity and related diseases of the obesity. The core of the invention lies in that it is found that the Muriaculum gardroncarteri bacterium has significant effects of preventing and treating obesity and related diseases, and the strain can inhibit body weight gain under high fat diet, reduce accumulation of abdominal fat and subcutaneous fat, improve dyslipidemia, reduce the level of total cholesterol (TCHO) and low density lipoprotein cholesterol (LDL-C) in serum, and improve the immunity of the human body, so that the Muriaculum gardroncarteri bacterium can be used for preventing and treating obesity and related diseases. Meanwhile, fatty degeneration and inflammatory response of the liver can be improved, and leptin resistance and insulin resistance can be improved.

The invention belongs to the technical field of medicines, and particularly relates to application of kinetin in preparation of medicines for preventing and / or treating obesity, fatty liver and liver injury induced by high fat. The kinetin has a potential anti-obesity effect. Results of embodiments show that the kinetin can significantly reduce weight gain of mice caused by high fat induction, and after the kinetin is administered, the body type and white fat of the mice are reduced, the glucose tolerance is increased, the insulin sensitivity is increased, and the UCP1 (uncoupling protein 1) level of brown fat of a kinetin administration group is increased, which indicates that the kinetin can play a role in resisting obesity.